Pharmacogene Variants Associated with Liver Transplant in a Twelve-Year Clinical Follow-Up.

Autores de IIS La Fe

• Luis Sendra Gisbert

  Autor

• Gladys Guadalupe Olivera Pasquini

  Autor

• Rafael López Andújar

  Autor

• Cristina Serrano Millan

  Autor

• Eva María Montalvá Orón

  Autor

• María José Herrero Cervera

  Autor

• Salvador F Aliño Pellicer

  Autor

Participantes ajenos a IIS La Fe

• Rojas LE

Grupos

• Farmacogenética

• Hepatología, Cirugia Hepatobiliopancreática y Trasplantes

Abstract

Some gene polymorphisms have been previously associated individually with tacrolimus efficacy and toxicity, but no long-term study to determine the role of pharmacogene variants in the clinical evolution of liver-transplanted patients has been addressed so far. In the present work, we analyzed the relation between highly-evidenced genetic polymorphisms located in relevant pharmacogenes and the risk of suffering premature death and other comorbidities such as cancer, diabetes mellitus, arterial hypertension, graft rejection, infections and nephrotoxicities in a cohort of 87 patients (8 were excluded due to early loss of follow-up) transplanted at Hospital La Fe in Valencia (Spain) during a 12-year follow-up. Employing a logistic regression model with false discovery rate penalization and Kaplan-Meier analyses, we observed significant association between survival rates and metabolizer genes. In this sense, our results show an association between MTHFR gene variants in donor rs1801133 (HR: 7.90; p -value: 0.032) and recipient rs1801131 (HR: 7.34; p -value: 0.036) and the group of patients who died during the follow-up period, supporting the interest of confirming these results with larger patient cohorts. In addition, donor polymorphisms in UGT1A9 metabolizer gene rs6714486 (OR: 0.13; p -value: 0.032) were associated with a lower risk of suffering from de novo cancer. Genetic variants in CYP2B6 metabolizer gene rs2279343 demonstrated an association with a risk of infection. Other variants in different locations of SLCO1A2 , ABCC2 and ABCB1 transporter genes were associated with a lower risk of suffering from type 2 diabetes mellitus , chronic and acute nephrotoxicities and arterial hypertension. Results suggest that pharmacogenetics-derived information may be an important support for personalized drug prescription, clinical follow-up and the evolution of liver-transplanted patients.

Keywords

• ABC, CYP, SLCO, immunosuppressant, pharmacogenetics